OSF HealthCare Foundation celebrated the completion of the 2,000th transcatheter aortic valve replacement (TAVR) procedure at ...

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement was noninferior to surgery for death and stroke at 1 year in a real-world ...

Transcatheter aortic valve replacement (TAVR) with a self-expanding valve still worked out better, at least in terms of ...

Boston Scientific (NYSE:BSX) announced today that it invested $1.5 billion in transcatheter aortic valve replacement (TAVR) ...

Medtronic (NYSE:MDT) today announced three-year results from the SMART trial comparing its Evolut heart valve to Edwards' ...

The deal gives Boston Scientific a 34% equity stake in MiRus and an option to acquire its TAVR platform by making additional payments totaling $3 billion.

Early hemodynamic valve deterioration (HVD) after transcatheter aortic valve replacement (TAVR, or TAVI) appeared to have clinical impact by the 4-year mark, according to registry data. By that point, ...